Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.

Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ

Open source

DOI: 10.1136/jitc-2024-009890
Published: 2025 Feb 9
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2024-009890,
  title = {Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.},
  author = {Landsburg DJ and Frigault MJ and Heim M and Foley SR and Hill B and Schofield G and Jacobson CA and Jaglowski S and Locke FL and Ram R and Riedell PA and Shah G and Popplewell LL and Tiwari R and Lim S and Majdan M and Masood A and Pasquini M and Turtle CJ},
  year = {2025},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2024-009890},
  url = {https://doi.org/10.1136/jitc-2024-009890}
}

RIS

TY  - JOUR
TI  - Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
AU  - Landsburg DJ
AU  - Frigault MJ
AU  - Heim M
AU  - Foley SR
AU  - Hill B
AU  - Schofield G
AU  - Jacobson CA
AU  - Jaglowski S
AU  - Locke FL
AU  - Ram R
AU  - Riedell PA
AU  - Shah G
AU  - Popplewell LL
AU  - Tiwari R
AU  - Lim S
AU  - Majdan M
AU  - Masood A
AU  - Pasquini M
AU  - Turtle CJ
PY  - 2025
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2024-009890
UR  - https://doi.org/10.1136/jitc-2024-009890
ER  -

APA

DJ, L., MJ, F., M, H., SR, F., B, H., G, S., CA, J., S, J., FL, L., R, R., PA, R., G, S., LL, P., R, T., S, L., M, M., A, M., M, P., & CJ, T. (2025). Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2024-009890

Source records

pubmed · retrieved 2026-09-25T12:47:09.051Z